GO
Loading...

Insurance

More

  • After ending 2007 with a gain of almost 29%, their best year since 1998, shares of Warren Buffett's Berkshire Hathaway have been showing some weakness in the New Year. Today's "Ahead of the Tape" column in The Wall Street Journal has an idea about what's pulling down BRK.

  • On the Line: NY Insurance Superintendent Eric Dinallo Thursday, 10 Jan 2008 | 11:06 AM ET

    The country's top insurance regulator tells Cramer his plan to get the business back on track - and why he reached out to Berkshire Hathaway.Investing can be confusing. Luckily, Cramer has mapped out some road rules for all you Home Gamers trying to navigate the jungle that is Wall Street. Think of it as "Mad Money 101" –- some fundamental advice to keep in mind as you play the market. Whether you're a first time investor or a seasoned financier, it's always good to remember the basics.

  • Central Park and midtown Manhattan are shown in this aerial view Wednesday, Aug. 29, 2007, in New York. (AP Photo/Mark Lennihan)

    Warren Buffett's brand-new municipal bond insurer, Berkshire Hathaway Assurance Corporation, has sold its first coverage, backing a $10 million bond issued by New York City yesterday.  Ajit Jain, who runs Berkshire's insurance businesses, tells the New York Times, "We're tip-toeing into the market, doing very small deals. We want to see if we can get the pricing that we find acceptable to us. Once we find this is real, we'll put in a lot more capital." He also describes how a call from a New York regulator played a key role.

  • The man who oversees the insurance operations for Warren Buffett's Berkshire Hathaway tells CNBC that Berkshire is talking with troubled bond insurers like MBIA and Ambac about a possible partnership or purchase, although it doesn't sound like anything major is imminent.  Ajit Jain's comment came in response to a question from Erin Burnett in a live interview on CNBC's Street Signs about why Berkshire chose to "build" its own bond insurer rather than buy an existing company like Ambac or MBIA.

  • Greenberg-Led Group Not Seeking Takeover of AIG Wednesday, 9 Jan 2008 | 4:09 PM ET

    Former American International Group Chief Executive Maurice "Hank" Greenberg said that a group he represents currently does not intend to solicit proxies from AIG shareholders, buy more AIG shares, or initiate a tender offer for the company.

  • Stop Trading!: Buy Coke Wednesday, 9 Jan 2008 | 3:51 PM ET

    The soda giant is going to $70, Cramer says. Also, the stocks that will signal the end of the Nasdaq decline.Investing can be confusing. Luckily, Cramer has mapped out some road rules for all you Home Gamers trying to navigate the jungle that is Wall Street. Think of it as "Mad Money 101" –- some fundamental advice to keep in mind as you play the market. Whether you're a first time investor or a seasoned financier, it's always good to remember the basics.

  • Warren Buffett, right, chairman of Berkshire Hathawy Inc., speaks to the media while Ron Ferguson, chairman and chief executive officer of General Re, listens in New York on Friday, June 19, 1998. Berkshire Hathaway Inc. is buying General Re for $22 billion worth of stock, adding one of the world's leading insurers of insurance companies to its portfolio. Berkshire announced Friday after the stock market closed that it would let General Re operate independently of its other insurance operations,

    A criminal corporate fraud trial that could bring Warren Buffett to the witness stand for some tough questioning is now underway in a federal courthouse in Hartford, Connecticut.  Emphasis on could.  Here's why I have my doubts.

  • Okay, the real "Granddaddy of 'em all" was actually this past Tuesday at the Rose Bowl (I promise that's my last reference to the amazing USC Trojans unless they win a split national championship), but the granddaddy of healthcare investment conferences begins on Monday in San Francisco.

  • AMGEN

    In a research note to clients this morning, Miller Tabak healthcare analyst Les Funtleyder writes about the FDA news I blogged about yesterday regarding Amgen's anemia drugs. He says, "...we believe the major 'leg down' in usage (of the anemia drugs) was last year and more studies assuming no major new negative revelations will only serve to continue deterioration but at a decelerating rate."

  • Sell Block: Bill Miller's Trip-Up at Legg Friday, 4 Jan 2008 | 11:18 AM ET

    The legendary investor just finished his second bad year in a row. So LM's a sell. But there's more to it than that, Cramer explains.Investing can be confusing. Luckily, Cramer has mapped out some road rules for all you Home Gamers trying to navigate the jungle that is Wall Street. Think of it as "Mad Money 101" –- some fundamental advice to keep in mind as you play the market. Whether you're a first time investor or a seasoned financier, it's always good to remember the basics.

  • Buffett Won't Have to Turn Over Documents, Judge Says Wednesday, 2 Jan 2008 | 2:23 PM ET

    A federal judge overseeing the trial of four former executives at the General Re unit of Berkshire Hathaway said the reinsurer need not turn over some documents involving Berkshire Chairman Warren Buffett.

  • Dendreon And Desmond: Flippin' Through The LA Times Wednesday, 2 Jan 2008 | 1:36 PM ET

    The "Dendreonians" have probably already seen it, but I wanted to call your attention to a pretty long piece that ran in the health section of the Los Angeles Times on Dec. 31st. It's about the grass-roots movement to get Dendreon's prostate cancer drug, Provenge, approved by the FDA. Here's the link.

  • Warren Buffett is finally moving to make some money from the nation's credit crisis by starting a new company that will insure debt issued by state and local governments. To make sure that he does indeed make money from the venture, he's promising not to make the same mistakes that have caused so many problems for long-time insurers like Ambac and MBIA: charging too little and taking on too much risk.

  • My 7 For '07: The Pharma Year in Review Friday, 28 Dec 2007 | 1:57 PM ET

    The seven biggest stories in my sectors in 2007? Avandia, Dendreon, Pfizer, Biogen were just a few of the topics that made this a fascinating year for the pharmaceuticals and biotechnology industries.

  • ACA Unit Taken Over by Maryland Regulators Thursday, 27 Dec 2007 | 11:47 AM ET

    ACA Capital Holdings said Maryland state regulators will now make many significant business decisions for its main bond insurance unit, as the bond insurer tries to stave off a cash crunch.

  • Glaxo's Avandia Scare: Market Feels Effects Thursday, 27 Dec 2007 | 10:46 AM ET

    A Merrill Lynch research note to clients titled, "Diabetics scared off therapy," contains some interesting observations about what's happened to the oral diabetes drug market in the wake of the Avandia safety scare earlier this year.

  • Higher Insurance Losses as Small Disasters Add Up Thursday, 27 Dec 2007 | 8:11 AM ET

    This year was marked by an absence of "megacatastrophes" but an increase in the number of smaller-scale natural disasters caused higher losses than the insurance industry saw in 2006, Munich Re said.

  • Wyeth: More Heartburn From Copycats? Wednesday, 26 Dec 2007 | 11:41 AM ET

    Shares of drugmaker Wyeth could remain under pressure this day after Christmas. At least two analysts are suggesting that Wyeth could be under assault by another generic drug company.

  • A New Hall of Shame Inductee Friday, 21 Dec 2007 | 7:48 PM ET

    MBIA CEO Gary Dunton "has the touch of a great novelist" when it comes to the company's financial reports, Cramer says.Investing can be confusing. Luckily, Cramer has mapped out some road rules for all you Home Gamers trying to navigate the jungle that is Wall Street. Think of it as "Mad Money 101" –- some fundamental advice to keep in mind as you play the market. Whether you're a first time investor or a seasoned financier, it's always good to remember the basics.

  • Did Genentech Back Down or Backpedal? Friday, 21 Dec 2007 | 12:11 PM ET

    So, it didn't take long after my Genentech blog entry got posted yesterday for me to receive an email and a voicemail from a Genentech spokesperson requesting a "clarification" on my take regarding the latest chapter in the Avastin vs. Lucentis brouhaha. I think I'm being spun.

Contact Insurance

  • CNBC NEWSLETTERS

    Get the best of CNBC in your inbox

    › Learn More